The Diagnostic Value of Cerebrospinal Fluid Neurogranin in Neurodegenerative Diseases.

Daria Krawczuk, Piotr Mroczko, Izabela Winkel, Barbara Mroczko

Abstract readReview

In one paragraph

Review in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

An organ-chip model of sporadic ALS using iPSC-derived spinal cord motor neurons and an integrated blood-brain-like barrier.Cell stem cell · 2025
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Daria KrawczukDepartment of Neurodegeneration Diagnostics, Medical University of Bialystok, Waszyngtona 15A, 15-269 Białystok, Poland.ORCID 0000-0002-6200-5232

Piotr MroczkoFaculty of Law, University of Bialystok, Mickiewicza 1, 15-213 Białystok, Poland.

Izabela WinkelDementia Disorders Centre, Medical University of Wroclaw, 50-425 Ścinawa, Poland.

Barbara MroczkoDepartment of Neurodegeneration Diagnostics, Medical University of Bialystok, Waszyngtona 15A, 15-269 Białystok, Poland.ORCID 0000-0002-4075-8479

Funding

Medical University in Białystok B.SUB.24.502, B.SUB.24.165

6 · The paper itself

Abstract

Synaptic pathology is crucial in neurodegenerative diseases (NDs), and numerous studies show a correlation between synaptic proteins and the rate of cognitive decline in Alzheimer's disease, Parkinson's disease, dementia, and Creutzfeldt-Jacob's disease. Due to the fact that altered synaptic function is considered a core feature of the pathophysiology of neurodegenerative disorders, synaptic proteins, such as neurogranin, may serve as a biomarker of these diseases. Neurogranin is a postsynaptic protein located in the cell bodies and dendrites of neurons, foremost in the cerebral cortex, hippocampus, and striatum. It has been established that neurogranin is involved in synaptic plasticity and long-term potentiation. Literature data indicate that cerebrospinal fluid neurogranin may be useful as a biomarker for more accurate diagnosis and prognosis of neurodegenerative diseases. In this review, the diagnostic value of cerebrospinal fluid neurogranin in most common neurodegenerative diseases is examined.

Indexed as

BiomarkersNeurodegenerative DiseasesNeurograninAlzheimer DiseaseAnimalsHumansBiomarkersNeurograninAlzheimer’s diseasebiomarkersCreutzfeldt–Jacob’s diseaseneurodegenerationneurograninParkinson’s disease

Identifiers

PMID39769345

DOI10.3390/ijms252413578

PMCPMC11677289

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.